Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Suzannah Harnor.

Newcastle AuthorsTitleYearFull text
Duncan Miller
Dr Suzannah Harnor
Dr Mathew Martin
Dr Richard Noble
Professor Steve Wedge
et al.
Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy2023
Dr Suzannah Harnor
Dr Celine Cano
Advanced approaches of developing targeted covalent drugs2022
Duncan Miller
Tristan Reuillon
Dr Lauren Molyneux
Dr Tim Blackburn
Dr Noel Edwards
et al.
Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor2022
Islam Al-Khawaldeh
Dr Christine Basmadjian
Dr Cinzia Bordoni
Dr Suzannah Harnor
Amy Heptinstall
et al.
An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK)2021
Dr Ian Hardcastle
Dr Ruth Bawn
Dr Tim Blackburn
Dr Celine Cano
Dr Sarah Cully
et al.
Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction2021
Christopher Matheson
Christopher Coxon
Dr Benoit Carbain
Dr Ian Hardcastle
Dr Suzannah Harnor
et al.
2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase2020
Dr Brian Ford
Dr Shruti Chachra
Ahmed Alshawi
Alfie Brennan
Dr Suzannah Harnor
et al.
Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge2020
Stephanie Myers
Duncan Miller
Dr Lauren Molyneux
Dr Mercedeh Arasta
Dr Ruth Bawn
et al.
Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD42019
Dr Simon Hill
Dr Michael Dunn
Dr Celine Cano
Dr Suzannah Harnor
Dr Ian Hardcastle
et al.
Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification2018
Dr Celine Cano
Dr Suzannah Harnor
Dr Elaine Willmore
Professor Steve Wedge
Targeting DNA-PK as a Therapeutic Approach in Oncology2018
Christopher Coxon
Dr Suzannah Harnor
Dr Mathew Martin
Dr Benoit Carbain
Emeritus Professor Bernard Golding
et al.
Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines2017
Dr Suzannah Harnor
Alfie Brennan
Dr Celine Cano
Inhibition of the DNA-Dependent Protein Kinase for Cancer Therapy2017
Dr Suzannah Harnor
James Pickles
Dr Celine Cano
Modulation of the DNA-Damage Response by Inhibitors of the Phosphatidylinositol 3-Kinase Related Kinase (PIKK) Family2017
Dr Suzannah Harnor
Alfie Brennan
Dr Celine Cano
Targeting DNA-Dependent Protein Kinase for Cancer Therapy2017
Dr Victorovich Zaytsev
James Pickles
Dr Suzannah Harnor
Dr Alistair Henderson
Mohammed Al Yasiri
et al.
Concise syntheses of bridged morpholines2016
Dr Susan Tudhope
Dr Yan Zhao
Dr Anita Wittner
Annalisa Bertoli
Santosh Adhikari
et al.
Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels2014
Dr Suzannah Harnor
Dr Tommy Rennison
Dr Martin Galler
Dr Celine Cano
Professor Roger Griffin
et al.
Synthesis of 3 '-deoxy-3'-fluorothymidine (FLT) 5 '-O-glucuronide: a reference standard for imaging studies with [18F]FLT2014
Annalisa Bertoli
Santosh Adhikari
Dr Suzannah Harnor
Dr Yan Zhao
Professor John Lunec
et al.
Validation studies with small-molecule modulators of the MDM2/MDMX-p53 binding interaction2014
Dr Emma Haagensen
Huw Thomas
Ian Wilson
Dr Suzannah Harnor
Sara Payne
et al.
The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [18F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice2013